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A majority of U.S. households are supplied
with disinfected water. Disinfection is neces-
sary to destroy pathogenic organisms and
prevent the outbreak of waterborne infec-
tious diseases. Such diseases are largely under
control in the United States, but waterborne
outbreaks resulting in disease and mortality
continue to occur (1). Although the beneﬁts
of water disinfection are well recognized,
there is an undesirable side effect of produc-
ing various disinfection by-products (DBPs)
when disinfectants such as chlorine and
ozone react with natural inorganic and
organic matter in the water.
The public health risks associated with
DBPs are not fully understood. In 1974 it
was discovered that some DBPs are carcino-
genic in laboratory animals (2,3). This raised
public concern about the possible adverse
health effects from exposure to DBPs, and in
1979 led the U.S. Environmental Protection
Agency (U.S. EPA) to regulate the level of
certain DBPs, trihalomethanes (THMs), in
the water supply. 
In November 1979, the U.S. EPA set an
interim maximum contaminant level (MCL)
for total THMs (the combination of chloro-
form, bromodichloromethane, chlorodibro-
momethane, and bromoform) of 0.10 mg/L
as an annual average (4). This standard
applied to any public water system that
serves at least 10,000 people and uses a dis-
infectant. In December 1998, the U.S. EPA
finalized the Stage 1 Disinfectants/
Disinfection Byproduct Rule (DBPR) (5) in
conjunction with the Interim Enhanced
Surface Water Treatment Rule (6).
Together, these rules attempt to balance the
control of health risks from DBPs against
the risks from pathogenic microbial organ-
isms. As a part of the Stage 1 DBPR, the
U.S. EPA lowered the total THM standard
(the MCL) to 0.080 mg/L and set MCLs of
0.060 mg/L for ﬁve haloacetic acids (mono-
chloro-, dichloro-, trichloro-, monobromo-,
and dibromoacetic acids [HAA5]), 0.010
mg/L for bromate, and 1.0 mg/L for chlo-
rite. THMs and HAA5 are by-products of
chlorination. Bromate is a byproduct of both
disinfection with ozone and chlorine diox-
ide, whereas chlorite is a chlorine dioxide
byproduct. The 1996 Safe Drinking Water
Act (7) amendments require the U.S. EPA
to publish a Stage 2 DBPR. The content of
the Stage 2 DBPR, including which DBPs
will be regulated, has not yet been ﬁnalized. 
The U.S. EPA has an extensive research
program to better characterize the potential
health effects and occurrence levels of several
DBPs, including those regulated under the
Stage 1 DBPR. It is preferable to have both
toxicity and occurrence data when setting
maximum contaminant level goals (MCLGs)
for drinking water standards to better deﬁne
public health risk. The U.S. EPA, in a collab-
orative testing program with the U.S.
National Toxicology Program (NTP), is
conducting 2-year cancer rodent bioassays,
transgenic mouse cancer assays, and medaka
fish cancer assays, as well as tests for repro-
ductive, developmental, immunologic, and
neurologic toxicities on several DBPs. In
addition, an information collection rule was
promulgated (8) to collect national occur-
rence information on 32 DBPs (Table 1).
The chemicals in the Stage 1 DBPR are
among the DBPs with the highest occurrence
in drinking water. However, hundreds of
other DBPs formed from treatment with vari-
ous disinfectants, including chlorine, have
been identiﬁed. There is a limited amount of
information on most of these DBPs beyond
their identification in water. In addition,
there are many unidentified DBPs, as evi-
denced by measurements of total organic
halides compared with known halogenated
DBPs (5). The U.S. EPA believes that the
standards in the Stage 1 DBPR will, to some
extent, control these other known and
unknown DBPs. The U.S. EPA must better
define the risk from the DBPs identified in
drinking water before it can determine
whether they are adequately controlled by cur-
rent standards. The two most important fac-
tors needed to characterize risk are occurrence
and toxicity. For most DBPs that have been
identiﬁed, few or no data are available in either
area. Further research on these DBPs is there-
fore necessary. Because there are hundreds of
DBPs for which there are few or no health or
occurrence data, there is a need for prioritiza-
tion before expensive toxicologic tests and
occurrence monitoring studies are initiated.
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Disinfection by-products (DBPs) are formed when disinfectants such as chlorine, chloramine, and
ozone react with organic and inorganic matter in water. The observations that some DBPs such as
trihalomethanes (THMs), di-/trichloroacetic acids, and 3-chloro-4-(dichloromethyl)-5-hydroxy-
2(5H)-furanone (MX) are carcinogenic in animal studies have raised public concern over the possi-
ble adverse health effects of DBPs. To date, several hundred DBPs have been identified. To
prioritize research efforts, an in-depth, mechanism-based structure–activity relationship analysis,
supplemented by extensive literature search for genotoxicity and other data, was conducted for
ranking the carcinogenic potential of DBPs that met the following criteria: a) detected in actual
drinking water samples, b) have insufﬁcient cancer bioassay data for risk assessment, and c) have
structural features/alerts or short-term predictive assays indicative of carcinogenic potential. A
semiquantitative concern rating scale of low, marginal, low-moderate, moderate, high-moderate,
and high was used along with delineation of scientiﬁc rationale. Of the 209 DBPs analyzed, 20
were of priority concern with a moderate or high-moderate rating. Of these, four were structural
analogs of MX and ﬁve were haloalkanes that presumably will be controlled by existing and future
THM regulations. The other eleven DBPs, which included halonitriles (6), haloketones (2),
haloaldehyde (1), halonitroalkane (1), and dialdehyde (1), are suitable priority candidates for future
carcinogenicity testing and/or mechanistic studies. Key words: DBPs, disinfection by-products, car-
cinogenic potential, drinking water, mechanism-based SAR analysis, prioritization, structure–activ-
ity relationship. Environ Health Perspect 110(suppl 1):75–87 (2002).
http://ehpnet1.niehs.nih.gov/docs/2002/suppl-1/75-87woo/abstract.html
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prioritization was designed for evaluating
which DBPs, if any, present a health concern
sufficient to warrant additional research to
better characterize the risk. Those DBPs con-
sidered to present a health concern would
ﬁrst be tested in a battery of appropriate in
vitro or in vivo screening assays. The results
could be used to decide which DBPs deserve
further studies such as acute/subchronic spe-
cialized animal tests for neurotoxicity,
immunotoxicity, developmental, reproduc-
tive, or system toxicity, and medium-term
tests for cancer (e.g., transgenic mouse,
medaka fish). Results from these studies
could help prioritize more expensive long-
term tests and mechanistic studies. In addi-
tion, occurrence studies and research on the
development of analytical methods for these
high-priority DBPs would also need to be
addressed. In this article we discuss the
process the U.S. EPA used to prioritize DBPs
for future testing, in which DBPs were exam-
ined by expert structure–activity relationship
(SAR) judgment with emphasis on genotoxic
cancer potential.
The SAR analysis in this study addresses
only the carcinogenic potential of DBPs.
There are other ongoing efforts for predict-
ing noncancer effects, including reproduc-
tive and developmental toxicity (9,10).
Cancer has been raised as an end point of
concern in epidemiologic studies (11–19).
In addition, cancer is often the most sensi-
tive health end point that is used to set
drinking water standards. Most important,
cancer concerns were addressed ﬁrst because
the predictive tools for evaluating the poten-
tial cancer risk are more developed than those
for other end points such as reproductive and
developmental effects.
Prioritization Approach
The U.S. EPA designed a simple prioritiza-
tion scheme for determining which DBPs
may require additional research (Figure 1).
First, the U.S. EPA compiled a list of DBPs
to consider for prioritization. More than 600
DBPs from various disinfectant combina-
tions that have been identiﬁed and cataloged
by the U.S. EPA (20) served as an important
reference. Additional DBPs were subse-
quently added as new information became
available (21,22). Of these, the U.S. EPA
considered only those DBPs found or
detected in actual drinking water samples.
DBPs found only through laboratory experi-
ments were excluded because these experi-
ments are often performed under conditions
that are not representative of actual water
treatment practices. Thus, there is uncer-
tainty as to whether DBPs identiﬁed in labo-
ratory experiments can actually be found in
drinking water samples. Several additional
criteria included eliminating DBPs with
incomplete chemical structure characteriza-
tions. In addition, chemicals believed to be
impurities from processes other than disin-
fection, such as leachates from treatment
plant materials and laboratory equipment
(e.g., naphthalene, 3-ethyl styrene), were
eliminated. The list of 252 remaining DBPs
was peer reviewed by chemists with expertise
in DBP formation and identification to
ensure, to the extent possible, that the chem-
icals in the list were all actual or probable
DBPs. After these criteria were applied, 239
DBPs remained for research prioritization. 
In the next step, the U.S. EPA identiﬁed
those DBPs that have or will have 2-year
cancer bioassay data and occurrence data suf-
ﬁcient for making a hazard assessment, and
those DBPs for which sufficient bioassay
data are/will be available but insufficient
occurrence data currently exist. The criteria
for judging if sufﬁcient toxicity data exist to
conduct a cancer assessment were as follows:
a) there is an MCLG from the Stage 1 DBP
rule or past drinking water rules; b) the
NTP, the U.S. EPA, or others have con-
ducted or will conduct a 2-year cancer bioas-
say; or c) there is an oral slope factor on the
agency’s Integrated Risk Information System
(IRIS) (23). The criteria for judging if sufﬁ-
cient occurrence data exist to derive a
national estimate of exposure were as fol-
lows: a) there is an MCLG from the Stage 1
DBP rule or past drinking water rules, or b)
the DBP is included in the information col-
lection rule for DBPs that is collecting
national occurrence data. Thirty DBPs
(Table 2) were identified in this step and
eliminated from SAR consideration. 
As discussed in detail below, the remain-
ing 209 DBPs were analyzed by expert judg-
ment SAR analysis. After DBPs of low
concern were identified, a literature search
for mutagenicity and other toxicity data was
performed for the remaining DBPs to pro-
vide additional input to the SAR analysis.
The DBPs were categorized by a semiquanti-
tative ranking scale of high (H), high–mod-
erate (HM), moderate (M), low-moderate
(LM), marginal (Mar), and low (L) concern.
Because these concern levels are based on
expert judgment relative to known carcino-
gens, there is no exact deﬁnition. As a guide-
line, the following narrative descriptions
have been used (24): a) H = highly likely to
be a potent multispecies, multitarget car-
cinogen even at low doses; b) HM = highly
likely to be an active multispecies/target car-
cinogen at moderate doses; c) M = likely to
be a moderately active multispecies/target
carcinogen at relatively high doses or active
single species/target carcinogen at low doses;
d) LM = likely to be weakly carcinogenic, or
carcinogenic toward a single species/target at
relatively high doses; e) Mar = likely to have
marginal carcinogenic activity or may be
weakly carcinogenic at doses at or exceeding
maximum tolerated doses; f ) and L =
unlikely to be carcinogenic. Table 3 lists all
209 DBPs together with their assignment to
their most appropriate structural chemical
classes and categorization of concern level.
The basic principles of mechanism-based
SAR analysis used for categorizing concern
levels of DBPs are discussed below.
Overview of Basic Principles
of the Structure–Activity
Relationship Approach
SAR analysis has been used to predict toxic
potential of chemicals for which test data
are limited or not available. SAR is an
indispensable tool to help prioritize research
and development on a compound by pro-
viding valuable initial information on its
hazard potential. For organic chemicals the
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Table 1. DBPs for which national occurrence data were collected in the information collection rule. 
DBP class Individual DBPs
Trihalomethanes Chloroform, bromodichloromethane, dibromochloromethane, bromoform
Haloacetic acids Tri-, di-, monochloroacetic acid, tri-, di-, monobromoacetic acid, bromochloro-, 
bromodichloro-, chlorodibromoacetic acid
Haloacetonitriles Tri-, dichloroacetonitrile, bromochloroacetonitrile, dibromoacetonitrile
Haloketones 1,1-Dichloropropanone, 1,1,1-trichloropropanone
Other halogenated compounds  Chloropicrin, chloral hydrate, cyanogen chloride
Aldehydes Formaldehyde, acetaldehyde, propanal, butanal, pentanal, glyoxal, methyl glyoxal
Inorganics Bromate, chlorite, chlorate
>600 DBPs in literature from
various disinfectant
combinations (20)
30 DBPs with sufficient
toxicity data (e.g., MCLG,
2-year cancer bioassay,
IRIS slope factor) excluded
Peer review
252 DBPs detected in
drinking water samples
with complete chemical
structure characterization
209 DBPs considered in SAR
evaluation of cancer concern
Figure 1. Selection of DBPs for SAR analysis.predictive capability of SAR analysis
combined with other toxicity information
has been demonstrated (25–28). Currently,
SAR analysis is most well developed for
chemicals and metabolites believed to initi-
ate carcinogenesis through covalent interac-
tion with DNA (i.e., DNA-reactive,
-mutagenic, -electrophilic, or -proelec-
trophilic chemicals). At a more limited scale
there is some SAR experience for predicting
carcinogenicity that does not involve DNA
reactive mechanisms but rather involves cel-
lular toxicity, pathophysiologic parameters,
or receptor-mediated mechanisms such as
Ah receptor, peroxisome proliferation, and
endocrine disruption (24,29–31).
Mechanism-based SAR analysis has been
effectively used by the U.S. EPA for many
years to assess the potential carcinogenic haz-
ard of new chemicals, for which there are no
or scanty data, under the Premanufacture
Notification program of the Toxic
Substances Control Act (32). The same
approach has been used in design of safer
chemicals (33) and pollution prevention
(34). An expert system (OncoLogic) has been
developed to systematize and codify the
agency’s SAR expertise in predicting carcino-
genic potential of chemicals (26). The princi-
pal authors of this present article have been
involved in these program activities for more
than a decade. The SAR predictions of the
cancer potential of DBPs in this article are
based mainly on human expert judgment,
with some input from the OncoLogic expert
system. A similar approach has been applied
to prospective prediction of the outcome of
NTP cancer bioassays (27). The predictive
performance of our approach relative to other
predictive methods has been afﬁrmed by an
independent evaluation (28). 
Mechanism-Based
Structure–Activity Analysis 
Essentially, mechanism-based SAR analysis
involves comparison of an untested chemical
with structurally related compounds for
which carcinogenic activity is known.
Considering the most probable mechanism(s)
of action, the structural features and func-
tional properties of the untested compound
are evaluated and compared with reference
compounds. All available knowledge and data
relevant to evaluation of carcinogenic poten-
tial of the untested chemical are considered.
These include a) SAR knowledge base of the
related chemicals; b) toxicokinetics and toxi-
codynamics parameters (including physico-
chemical properties, route of potential
exposure, and mode of activation or detoxiﬁ-
cation) that affect the delivery of biologically
active intermediates to target tissue(s) for
interaction with cellular macromolecules or
receptors; and c) supportive noncancer screen-
ing or predictive data known to correlate to
carcinogenic activity. A prediction of carcino-
genic potential involves integration of all this
available information with human expert
intuition and judgment. 
In evaluating the DBPs both structural
and functional criteria were applied. The
structural criteria and methodology for
assessing carcinogenic potential of chemicals
have been discussed in detail in previous
reviews (26,27). Basically, the structural
moieties or fragments that may contribute to
carcinogenic activity through a perceived or
postulated mechanism are identiﬁed, and the
modifying role of the rest of the molecule to
which the structural moiety/fragment is
attached is evaluated. Whenever possible,
comparison is made to a structurally related
reference compound with known carcino-
genic activity (tested preferably by the same
route of administration as the chemical in
question) to evaluate whether the difference
in chemical structures may lead to an
increase or decrease in carcinogenic activity.
Electrophiles can interact with DNA and
potentially lead to mutagenesis. The identiﬁ-
cation of electrophiles and their precursors is
thus fundamental to the prediction of muta-
genic carcinogens. Some of the commonly
encountered electrophiles or electrophilic
intermediates in carcinogenesis include carbo-
nium ions (alkyl-, aryl-, benzylic), nitrenium
ions, epoxides and oxonium ions, aldehydes,
polarized double bonds (α,β-unsaturated car-
bonyls or carboxylates), peroxides, free radi-
cals, and acylating intermediates (27).
For compounds that are metabolically
activated, resonance stabilization provides
reactive intermediates a longer reactive life-
time. Structural features that may furnish res-
onance stabilization include conjugated
double bonds, an aryl moiety (especially those
capable of providing long resonance path-
ways), ring positions that allow several reso-
nance forms, and structures that allow
reversible cyclization of reactive intermediates.
The molecule to which a reactive moiety
is attached may significantly affect its car-
cinogenic potential. Many potent carcino-
gens (e.g., aflatoxin B1, benzo[a]pyrene)
have a relatively planar molecular size and
shape favorable for DNA intercalation in
addition to having a reactive functional
group. Attachment of a reactive electrophilic
group to normal cellular molecular con-
stituents may also enhance carcinogenic
activity (e.g., attaching the moderately car-
cinogenic nitrogen mustard to uracil yields a
more potent carcinogen, uracil mustard),
probably by serving as a carrier to reach the
target macromolecule. Conversely, the pres-
ence of highly hydrophilic groups or bulky
substituents that may affect metabolic activa-
tion or molecular planarity tends to decrease
or eliminate carcinogenic activity.
The structural basis for identifying recep-
tor-mediated carcinogens is considerably less
understood and is dependent on the type of
receptor believed to be involved. Some of the
structural features useful in identifying these
carcinogens include a) planar tricyclic mole-
cule with lateral ring substitution for Ah
receptor–mediated 2,3,7,8-tetrachloro-
dibenzo-p-dioxin–related chemicals (35,36);
b) nonmetabolizable acids (such as branching
at the carbon next to the acid-bearing car-
bon) for peroxisome proliferator–type car-
cinogens (29); and c) a molecular descriptor
containing a phenolic group 6 angstroms
away from a lipophilic moiety for at least
some types of hormonal carcinogens (30). In
addition to the information on structural
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Table 2. DBPs that have or will have sufﬁcient data for hazard assessment.
DBPs with cancer and occurrence data DBPs with cancer data but lacking occurrence data
Acetaldehyde (48,71) Benzaldehyde (47)
Bromate (48,71) 1,4-Benzenedicarboxylic acid (terephthalic acid) (70)
Bromochloroacetic acida (69,71) Benzyl chloride (47)
Bromodichloroacetic acida (69,71) 3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone (MX) (50)
Bromodichloromethane (47,48,71) Dichloromethane (47)
Bromoform (48,71) 1,4-Dioxane (47)
Chloral hydratea (69,71) Hexachloroethane (47)
Chloratea (69,72) Hydrogen peroxide (48)
Chloroform (48,71) 4-Methyl-2-pentanonea (69)
Chloropicrin (47,71)
Dibromoacetic acida (69,71)
Dibromoacetonitrile (48,71)
Dibromochloroacetic acida (69,71)
Dibromochloromethane (47,71)
Dichloroacetic acid (48,71)
2,4-Dichlorophenol (47,73)
Formaldehyde (48,71)
Glyoxala (69,71)
Monochloroacetic acid (47,71)
Trichloroacetic acid (48,71)
2,4,6-Trichlorophenol (47,48,73)
aCurrently under study or selected for testing.Reviews, 2002 • Woo et al.
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1. Acetone [64-64-1] Nonhalogenated ketones L
2. Benzeneacetaldehyde [122-78-1] Nonhalogenated aldehydes Mar
3. 1,2-Benzenedicarboxylic acid [88-99-3] Nonhalogenated acids L
(phthalic acid)
4. 1,3-Benzenedicarboxylic acid  [121-91-5] Nonhalogenated acids L
(isophthalic acid) 
5. 1,2,3-Benzenetricarboxylic acid  [36362-97-7] Nonhalogenated acids L
(hemimellitic acid)
6. 1,2,4-Benzenetricarboxylic acid [528-44-9] Nonhalogenated acids L
(trimellitic acid)
7. 1,3,5-Benzenetricarboxylic acid [554-95-0] Nonhalogenated acids L
(trimesic acid)
8. 1,4-Benzodioxin [255378] Nonhalogenated  aromatics LM
9. Benzoic acid [65-85-0] Nonhalogenated acids L
10. Benzonitrile [100-47-0] Nonhalogenated aromatics Mar
11. Benzyl cyanide [140-29-4] Nonhalogenated aromatics L
12. 2,6-Bis-(1,1-dimethylethyl)- [719-22-2] Nonhalogenated aromatics Mar
2,5-cyclohexadiene-1,4-dione
13. 1,2-Bis-(1-methylethenyl)- Nonhalogenated aromatics Mar
benzene
14. Bromoacetic acid [79-08-3] Haloacids Mar
15. Bromoacetonitrile [590-17-0] Halonitriles LM
16. Bromoamine Haloamines/amides L
17. 2-Bromobenzothiazole [2515-40-7] Halogenated aromatics LM
18. 2-Bromobutane (sec-butyl [78-76-2] Haloalkanes/alkenes LM
bromide)
19. Bromochloroacetonitrile [83463-62-1] Halonitriles M
20. Bromochloroamine [77352-23-9] Haloamines/amides L
21. Bromochloroiodomethane [34970-00-8] Haloalkanes/alkenes M
22. Bromochloromethane [74-97-5] Haloalkanes/alkenes M
23. Bromochloromethyl acetate Acetate of haloalcohols LM
24. 1,1-Bromochloropropanone [513-88-2] Haloketones LM
25. 3-Bromo-4-(dibromomethyl)-5- Halofuranones and related HM
hydroxy-2(5H)-furanone compounds
(BMX-3)
26. Bromodichloroacetaldehyde [34619-29-9] Haloaldehydes LM
27. Bromodichloroacetonitrile [60523-73-1] Halonitriles LM
28. Bromodichloronitromethane [918-01-4] Halonitroalkanes LM
29. 1-Bromo-1,1-dichloropropanone [16995-35-0] Haloketones LM
30. Bromopicrin [464-10-8] Halonitroalkanes LM
31. 3-Bromopropyl-chloromethyl Haloethers Mar  (oral), 
ether HM
(inhaled) 
32. Butanal [123-72-8] Nonhalogenated aldehydes L
33. Butanedial [638-37-9] Nonhalogenated aldehydes M
34. Butanoic acid  [107-92-6] Nonhalogenated acids L
35. Butanone [78-93-3] Nonhalogenated  ketones L
36. cis-Butenedioic acid (maleic acid) [110-16-7] Nonhalogenated acids L
37. trans-Butenedioic acid [110-17-8] Nonhalogenated acids L
(fumaric acid)
38. 2-(2-Butoxyethoxy)-ethanol [112-34-5] Other nonhalogenated  L 
(di(ethylene glycol)butyl ether) organics
39. 2-[2-(2-Butoxyethoxy) [143-22-6] Other nonhalogenated  L
ethoxy]-ethanol organics
40. 2-tert-Butylmaleic acid  Nonhalogenated acids L
41. Chlorite [14998-27-7] Inorganics LM
42. Chloroacetaldehyde [107-20-0] Haloaldehydes LM
43. Chloroacetonitrile [107-14-2] Halonitriles LM
44. 3-Chloro-4-(bromochloro- Halofuranones and related HM
methyl)-5-hydroxy-2(5H)- compounds
furanone (BMX-1)
45. Chlorobutanedioic acid [16045-92-4] Haloacids Mar
46. 3-Chloro-2-butanol [563-84-8] Other halogenated organics Mar
47. 3-Chloro-2-butanol acetate [54192-20-0] Acetate of haloalcohols Mar
48. 2-Chlorobutenedioic acid Haloacids Mar
49. 2-Chlorocyclohexanone [822-87-7] Haloketones LM
50. Chlorodibromoacetaldehyde Haloaldehydes LM
51. 3-Chloro-4-(dibromo- [132059-52-0] Halofuranones and related HM
methyl)-5-hydroxy-2(5H)- compounds
furanone (BMX-2)
52. (E)-2-chloro-3-(dichloromethyl)- Halofuranones and related Mar
butenedioic acid (ox-EMX) compounds
53. 2-Chloro-3-(dichloromethyl)- Halofuranones and related Mar
butenedioic acid (ox-MX) compounds
54. 3-Chloro-4-(dichloromethyl)- [122551-89-7] Halofuranones and related LM 
2-(5H)-furanone (red-MX) compounds
55. (E)-2-Chloro-3-(dichloromethyl)- Halofuranones and related LM
4-oxobutenoic acid (EMX) compounds
56. 2-Chlorododecane [2350-11-0] Haloalkanes/alkenes L
57. (2-Chloroethenyl)-benzene [622253] Halogenated aromatics LM
58. 1-Chloro-2-ethoxy-2-methoxy Haloethers LM
ethane
59. 4-Chloro-3-keto-1-butanal Haloaldehydes LM
60. Chloromethane [74-87-3] Haloalkanes/alkenes LM
61. 2-Chloro-3-methyl-cis- Haloacids Mar
butenedioic acid
62. 1-Chlorooctane [111-85-3] Haloalkanes/alkenes Mar
63. 2-Chlorophenol [95-57-8] Halogenated  aromatics L
64. 2-Chloropropanoic acid [598-78-7] Haloacids Mar
65. 3-Chloropropanoic acid [107-94-8] Haloacids LM
66. Chloropropanone [78-95-5] Haloketones LM
67. 1-Chloro-3,3,3-trichloro-1- Haloamines/amides LM
propen-1-amine
68. Cyanoformaldehyde [4471-47-0] Nonhalogenated aldehydes LM
69. Cyanogen bromide [506-68-3] Halonitriles L
70. Cyanogen chloride [506-77-4] Halonitriles L
71. Cyclododecane  [294-62-2] Other nonhalogenated organics L
72. Decanal [112-31-2] Nonhalogenated aldehydes L
73. Decanoic acid [334-48-5] Nonhalogenated acids L
74. Dibromoamine Haloamines/amides L
75. Dibromochloroacetonitrile [144772-39-4] Halonitriles LM
76. Dibromomethane [74-95-3] Haloalkanes/alkenes M
77. 1,1-Dibromopropanone [867-54-9] Haloketones LM
78. 2,6-Di-tert-butyl-4-nitrophenol [728-40-5] Nonhalogenated aromatics LM
79. Dichloroacetaldehyde [70-02-7] Haloaldehydes M
80. 2,2-Dichloroacetamide [683-72-7] Haloamines/amides LM
81. Dichloroacetonitrile [3018-12-0] Halonitriles LM
82. 4,6-Dichloro-1,3-benzenediol [137-19-9] Halogenated aromatics L
83. 2,3-Dichloro-3-bromopropane- Halonitriles M
nitrile
84. 2,3-Dichlorobutane [7581-97-7] Haloalkanes/alkenes LM
85. 3,4-Dichlorobutanenitrile Halonitriles M
86. 2,2-Dichlorobutanoic acid [13023-00-2] Haloacids Mar
87. 1,1-Dichloro-2-butanone [2648-56-8] Haloketones LM
88. 3,3-Dichloro-2-butanone [2648-57-9] Haloketones Mar
89. Dichloroiodomethane [594047] Haloalkanes/alkenes M
90. 1,2-Dichloro-2-methyl butane [23010-04-0] Haloalkanes/alkenes LM
91. 2,3-Dichloro-4-oxobutenoic acid [87-56-9] Halofuranones and related  M
(mucochloric acid) compounds
92. 4,5-Dichloro-2-pentanol Other halogenated organics LM
93. 2,2-Dichloro-3-pentanone Haloketones Mar
94. 2,2-Dichloropropanoic acid [75-99-0] Haloacids Mar
95. 1,1-Dichloropropanone [513-88-2] Haloketones LM
96. 1,3-Dichloropropanone [534-07-6] Haloketones M
97. 3,3-Dichloropropenoic acid [13167367] Haloacids Mar
98. Dihydro-4,5-dichloro-  Halofuranones and related LM
2(3H)furanone compounds
99. 3,4-Dihydroxybenzoic acid [99-50-3] Nonhalogenated aromatics L
100. 2,2-Dimethylbutanedioic acid [597-43-3] Nonhalogenated acids L
(2,2-dimethylsuccinic acid)
101. 2,5-Dimethylcyclopentanone [4041092] Nonhalogenated ketones L
102. Dimethyl glyoxal [431-03-8] Nonhalogenated ketones LM
103. 2,6-Dimethyl-2,5- [504-20-1] Nonhalogenated ketones L
heptadiene-4-one 
104. 2,2-Dimethylpentanedioic acid [681-57-2] Nonhalogenated acids L
105. 6,10-Dimethyl-5,9- [3796-70-1] Nonhalogenated ketones L
undecadiene-2-one
106. Dioxobutanoic acid [4374-46-3 Nonhalogenated acids L
107. 1,2-Dioxopropanoic acid Nonhalogenated acids Mar
108. Dodecanal [112-54-9] Nonhalogenated  aldehydes L
(Continued)
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109. Dodecanoic acid [143-07-7] Nonhalogenated acids L
110. 4-Dodecyl-5-ethyl- Other nonhalogenated organics L
2(5H)-furanone
111. 1-Ethoxy-1-hydroxymethane Other nonhalogenated organics L
112. 2-Ethyl-3-methylmaleic acid  Nonhalogenated acids L
113. Glyoxylic acid [298-12-4] Nonhalogenated acids L
114. Heneicosanoic acid [2363-71-5] Nonhalogenated acids L
115. Heptadecanoic acid [506-12-7] Nonhalogenated acids L
116. Heptanal [111-71-7] Nonhalogenated aldehydes L
117. Heptanedioic acid [111-16-0] Nonhalogenated acids L
118. Heptanenitrile [629-08-3] Other nonhalogenated organics L
119. Heptanoic acid [111-14-8] Nonhalogenated acids L
120. Hexachloropropanone [116-16-5] Haloketones LM
121. Hexadecanoic acid [57-10-3] Nonhalogenated acids L
122. 9-Hexadecanoic acid [10030-73-6] Nonhalogenated acids L
123. Hexanal [66-25-1] Nonhalogenated aldehydes L
124. Hexanedioic acid (adipic acid)  [124-04-9] Nonhalogenated acids L
125. Hexanedioic acid, dioctyl ester  Other nonhalogenated  L
organics
126. Hexanoic acid  [142-62-1] Nonhalogenated acids L
127. 3-Hexanone [589-38-8] Nonhalogenated ketones L
128. 2-Hexenal [505-57-7]-cis Nonhalogenated aldehydes LM
[6728-26-3]-trans
129. 3-Hydroxybenzoic acid [99-06-9] Nonhalogenated acids L
130. 1-[4-(1-Hydroxy-1-methylethyl) Nonhalogenated ketones L
phenyl]-ethanone
131. 1-Hydroxy-3-methyl-2-hexene  Other nonhalogenated organics L
132. 5-Hydroxy-5-trichloromethyl- Halofuranones and related LM
2-furanone compounds
133. Hypobromite [14380-62-2] Inorganics LM
134. Methane sulfonyl chloride [124-63-0] Other halogenated organics Mar
135. 1-[2-(2-Methoxy-1- [20324-33-8] Other nonhalogenated  L
methylethoxy)-1- organics
methylethoxy]-2-propanol
136. 3-Methylbenzoic acid  [99-04-7] Nonhalogenated acids L
137. 4-Methylbenzoic acid [99-94-5] Nonhalogenated acids L
138. 3-Methylbutanal [590-86-3] Nonhalogenated aldehydes Mar
(isoamylaldehyde)
139. 3-Methylbutane nitrile [625-28-5] Other nonhalogenated  L
organics
140. 2-Methylbutanoic acid [32231-50-8] Nonhalogenated acids Mar
(2-methylbutyric acid)
141. 3-Methyl-1,2,4- [4505-54-8] Nonhalogenated ketones L
cyclopentanetrione
142. 2-Methyl decanal [19009-56-4] Nonhalogenated aldehydes L
143. 2-Methyl-3,3-dichloro-2- Haloethers Mar (oral), 
propenyl dichloromethyl  H (inhaled)
ether
144. 1-[4-(1-Methylethenyl)phenyl]- [53509-04-6] Nonhalogenated ketones L
ethanone
145. 4-(1-Methylethyl)-benzene [536-60-7] Nonhalogenated aromatics L
methanol
146. 5-Methyl-2-furancarboxylic acid [1917-15-3] Nonhalogenated acids L
147. Methyl glyoxal [78-98-8] Nonhalogenated aldehydes LM
148. 6-Methyl-5-hepten-2-one [409-02-9] Nonhalogenated  ketones L
149. 3-Methyl-2,4-hexanedione [4220-52-4] Nonhalogenated ketones LM
150. 5-Methyl-3-isoxazolamine [1072-67-9] Other nonhalogenated  L
organics
151. 2-Methylpentanedioic acid  [18069-17-5] Nonhalogenated acids L
(2-methylglutaric acid)
152. 2-Methyl pentanoic acid [97-61-0] Nonhalogenated acids Mar
153. 3-Methyl-2-pentanone [565-61-7] Nonhalogenated  ketones L
(sec-butyl methyl ketone)
154. Methyl propanal [78-84-2] Nonhalogenated aldehydes L
(isobutylaldehyde)
155. 2-Methyl propanoic acid  [79-31-2] Nonhalogenated acids Mar
156. Nitrodibromomethane [598-91-4] Halonitroalkanes M
157. 1-Nitro-1,1-dichloroethane [594729] Halonitroalkanes LM
158. Nonanal [124-19-6] Nonhalogenated aldehydes L
159. Nonanedioic acid [123-99-9] Nonhalogenated acids L
(azelaic acid)
160. Nonanoic acid [112-05-0] Nonhalogenated acids L
161. Octadecanoic acid (stearic acid) [57-11-4] Nonhalogenated acids L
162. Octanal [124-13-0] Nonhalogenated  aldehydes L
163. Octanedioic acid (suberic acid) [505-48-6] Nonhalogenated acids L
164. Octanoic acid [124-07-2] Nonhalogenated acids L
165. 2-Oxobutanedioic acid  [328-42-7] Nonhalogenated acids L
(ketosuccinic acid)
166. 2-Oxopentanoic acid  [1821-02-9] Nonhalogenated acids L
(2-ketovaleric acid)
167. 4-Oxopentanoic acid [123-76-2] Nonhalogenated acids L
168. Oxopropanedioic acid  [473-90-5] Nonhalogenated acids L
(ketomalonic acid)
169. 2-Oxopropanoic acid [127-17-3] Nonhalogenated acids L
(pyruvic acid)
170. Pentachloropropanone [1768-31-6] Haloketones LM
171. Pentadecanoic acid [1002-84-2] Nonhalogenated acids L
172. Pentanal [110-62-3] Nonhalogenated aldehydes L
173. Pentanedioic acid (glutaric acid) [110-94-1] Nonhalogenated acids L
174. Pentanoic acid [109-52-4] Nonhalogenated acids L
175. Phenylacetic acid [103-82-2] Nonhalogenated acids L
176. 1,1-(1,4-Phenylene)bis-ethanone [1009-61-6] Nonhalogenated aromatics L
177. Propanal [123-38-6] Nonhalogenated aldehydes LM
178. Propanedioic acid (malonic acid) [141-82-2] Nonhalogenated acids L
179. Tetrachlorocyclopropene [6262-42-6] Haloalkanes/alkenes LM
180. 1,1,5,5-Tetrachloropentane [17655-64-0] Haloalkanes/alkenes Mar
181. 1,1,1,3-Tetrachloropropanone [632-21-3] Haloketones LM
182. 1,1,3,3-Tetrachloropropanone [16995-35-0] Haloketones LM
183. Tetracosanoic acid [557-59-5] Nonhalogenated acids L
(lignoceric acid)
184. Tetradecanal [124-25-4] Nonhalogenated aldehydes L
185. Tetradecanoic acid [544-63-8] Nonhalogenated acids L
186. Tribromoacetaldehyde [115-17-3] Haloaldehydes LM
187. Tribromoacetic acid [75-96-7] Haloacids LM
188. Tribromoacetonitrile [75519-19-6] Halonitriles LM
189. 1,1,1-Tribromo-2-bromo- Haloalkanes/alkenes M
2-chloroethane
190. 2,2,2-Trichloroacetamide [594-65-0] Haloamines/amides Mar
191. Trichloroacetonitrile [545-06-2] Halonitriles LM
192. 1,1,1-Trichloro-2-butanone Haloketones LM
193. cis-2,3,4-Trichloro-2-butene Halonitriles M
nitrile
194. trans-2,3,4-Trichloro-2-butene Halonitriles M
nitrile
195. 2,2,4-Trichloro-1,3- Haloketones LM
cyclopentenedione
196. 3,3,3-Trichloro-2-methyl-1- [4749-27-3] Haloalkanes/alkenes LM
propene
197. 5,5, 5-Trichloro-4-oxopentanoic Haloacids Mar
acid
198. 1,1,1-Trichloropropanone [918-00-3] Haloketones LM
199. 1,1,3-Trichloropropanone [921-03-9] Haloketones M
200. Trichloropropenenitrile Halonitriles M
201. Tridecanal [10486-19-8] Nonhalogenated aldehydes L
202. Tridecanedioic acid (1,11- [505-52-2] Nonhalogenated acids L
unedecane dicarboxylic acid;
brassylic acid)
203. Tridecanoic acid [638-53-9] Nonhalogenated acids L
204. 2,6,6-Trimethyl-2-cyclohexene- [1125-21-9] Nonhalogenated ketones Mar
1,4-dione
205. 2,3,4-Trimethylcyclopent-2- [28790-86-5] Nonhalogenated ketones Mar
en-1-one
206. 1,3,3-Trimethyl-1,7-oxabicyclo- Nonhalogenated ketones Mar
[4.1.0]-heptane-2,5-dione
207. Undecanal [112-44-7] Nonhalogenated aldehydes L
208. Undecane [1120-21-4] Other  nonhalogenated  L
organics
209. Undecanoic acid [112-37-8] Nonhalogenated acids L
Table 3. Continued.
CAS Concern CAS Concern
Chemical name number Chemical class level Chemical name number Chemical class levelbasis of receptors, functional criteria using
short-term test data can also be used.
Functional criteria involve consideration
of all the available short-term noncancer pre-
dictive data and pharmacologic and toxico-
logic capabilities correlated or associated
with carcinogenic activity. Functional crite-
ria complement structural criteria because
structural considerations alone cannot fore-
cast entirely new types of carcinogens.
Furthermore, functional criteria may serve as
a means to confirm or cast doubt on the
mechanistic assumptions made in applying
structural criteria. Information that is highly
useful for predicting carcinogenic potential
includes data on oncogenes, tumor suppres-
sor genes, genotoxicity and/or ability to bind
covalently to DNA, apoptosis, cellular pro-
liferation, immunosuppression, and sub-
chronic toxicity end points that are
indicative or suggestive of carcinogenic
potential. Ideally, all of the available data
should be evaluated with respect to predic-
tive capability, strength of evidence, and rel-
evance to the carcinogenic process and then
integrated. Positive predictive tests and data
covering all aspects of the carcinogenic
process (initiation, promotion, and progres-
sion) should be given more weight than
multiple tests detecting the same mechanistic
end point (24).
Conditions of Hazard
Expression (Routes of
Exposure)
An individual may be exposed to DBPs by
different routes of exposure (e.g., inhalation
from showering, dermal from bathing, oral
from tap water consumption). In evaluating
the carcinogenic potential of a compound, it
is important to consider the route of expo-
sure because the hazard and risk posed by a
compound may vary by exposure route (37).
Delivery of the reactive intermediate to target
macromolecules such as DNA is crucial for
carcinogenic activity, and exposure routes
such as inhalation and injection are often
required for maximal activity for direct-act-
ing reactive chemicals. For example, elec-
trophiles such as aldehydes are DNA reactive,
but this reactivity also means they are readily
detoxiﬁed by cellular-protective nucleophiles
such as glutathione (GSH). Their toxicity,
therefore, tends to be localized to the port of
entry. Thus aldehydes, which are of cancer
concern via inhalation, pose a lower cancer
concern via the oral route because they are
readily oxidized to acids before they can react
with DNA. However, subpopulations with
genetically diminished capability to detoxify
aldehydes may be at higher risk. The SAR
predictions presented in this document focus
mainly on the hazard potential via ingestion
of drinking water, a major route of exposure
to DBPs. Inhalation exposure to some
volatile DBPs may occur through bathing or
showering. In general, for the purpose of
ranking hazard potential, DBPs that require
metabolic activation (e.g., THMs) should
have similar hazard potential whether via oral
or inhalation, whereas DBPs that are highly
reactive direct-acting chemicals (e.g.,
α-haloethers if they could actually remain
reactive through the water delivery system)
are expected to have higher concern via
inhalation than via oral route. 
Literature Search Approach
In support of the SAR analysis of DBPs of
greater than low concern, a literature search
was performed using chemical abstract num-
bers. There were several DBPs for which a
literature search was not performed because
Chemical Abstracts Service (CAS) registry
numbers could not be found in the CAS
Scientific and Technical Network online
database (38). For some DBPs, information
on closely related compounds was searched. 
Because the present SAR study empha-
sized predicting genotoxic carcinogens,
selected databases were used. Both the
Environmental Mutagen Information
Center-Front and Back Files (EMIC/
EMICBACK) (39) were searched.
EMICBACK, developed and maintained by
the Oak Ridge National Laboratory, is a bib-
liographic database on compounds tested for
genotoxic activity. The database contains lit-
erature published from 1950 to 1990 and
includes some references published before
1950. EMIC covers publications from 1989
to the present. The Chemical Carcinogenesis
Research Information System (CCRIS) (40),
developed and sponsored by the National
Cancer Institute, was also searched. CCRIS
contains information from carcinogenicity,
mutagenicity, tumor promotion, and tumor
inhibition studies that have been evaluated
for acceptability by experts in carcinogenesis.
CCRIS contains 7,000 chemical records.
Additionally, the NTP (41), IRIS (23), and
the Agency for Toxic Substances and Disease
Registry (ATSDR) toxicological proﬁles (42)
were searched for availability of cancer bio-
assay data. Although the EMIC/EMICBACK
and CCRIS databases were searched, some
information on mutagenicity and carcino-
genicity may have been missed, in particular,
information on metabolism and mode of
action (e.g., cell proliferation, apoptosis). 
Mutagenicity and carcinogenicity data
were gathered from either abstracts or actual
publications and compiled into a summary
table listing the chemical name, CAS num-
ber, test, strain, method, result, dose, and
publication reference. This information was
then used to assist in the SAR predictions for
DBPs of greater than low concern.
Structure–Activity
Relationships Cancer
Prediction for Disinfection 
By-Products
Prior to the SAR analysis the U.S. EPA
determined that those DBPs ranked as mod-
erate, high-moderate, or high would be the
priority candidates for future testing. This
was decided because of the large number of
DBPs involved. If a chemical with few
occurrence data was determined to be of a
higher concern, then further toxicity
research on the chemical might be justiﬁed.
If, however, a chemical was determined to be
of a lower concern, some occurrence data
beyond mere identiﬁcation would have to be
obtained before testing would be warranted. 
SAR predictions were made for 209
DBPs (Table 3). The DBPs were first
reviewed to identify chemicals with low
concern. Judgments of low cancer concern
were based on structural similarity to chemi-
cals with negative cancer data, a lack of
structural alert for genotoxicity, or presence
of structural features suggestive of low can-
cer risk via the oral route (26,27,33). Once
the DBPs of low concern were removed
from the list, a literature search was done for
the remaining DBPs. It should be noted
that literature was not found in EMIC/
CCRIS/NTP/IRIS/ATSDR databases for
many of the DBPs. Thus, the mechanism-
based SAR predictions relied heavily on
expert judgment and experience. SAR
assumptions and conclusions for concern
levels and specific classes of DBPs are
discussed below.
Distribution of Disinfection
By-Products within
Structure–Activity
Relationship Concern Levels
and Structural Classes
Table 4 summarizes the structural class and
concern level distribution of the 209 DBPs
Of the 209 DBPs examined, none are consid-
ered to be of high concern. Only 20 (<10%)
are predicted to have a concern level of mod-
erate or high-moderate. With one exception,
all these compounds are halogenated, with
most of them belonging to the structural
classes of halofuranones, haloalkanes/alkenes,
halonitriles, and haloketones. A detailed
analysis of these four classes will be presented.
Haloacids would have constituted a major
class of concern. However, because several
haloacids have already been tested or selected
for testing (Tables 1 and 2), they are not con-
sidered in detail in the present study. Outside
of the four major classes of concern, one
haloaldehyde (dichloroacetaldehyde), one
halonitroalkane (dibromonitromethane), and
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are considered of moderate concern.
Dichloroacetaldehyde has been given a
moderate concern because it is a potential
cross-linking agent. It can also be readily
oxidized to dichloroacetic acid, which has
been shown to be a rodent carcinogen with
multiple mechanisms of action (43–45).
Dibromonitromethane has been given a
moderate concern because the corresponding
dichloronitromethane is believed to be the
proximate mutagen of chloropicrin (46). The
replacement of chlorine by bromine should
make it a more potent mutagen because
bromine is a better leaving group. The struc-
turally related nitromethanes, particularly
tetranitromethane, are carcinogenic, whereas
chloropicrin (trichloronitromethane) is non-
carcinogenic in mice and inconclusive in rats
(47). Butanedial is the only nonhalogenated
DBP given a moderate concern in the pre-
sent study. This compound has two terminal
reactive aldehydes separated by two methyl-
ene groups, which should make it a highly
favorable cross-linking agent. 
The majority (131/209) of the DBPs in
this study are considered to have low
(98/209) or marginal (33/209) cancer con-
cern. Most of these compounds are nonhalo-
genated carboxylic acids, ketones, aldehydes,
and miscellaneous organic compounds.
Nonhalogenated hydrophilic carboxylic
acids are not of concern because they are
unlikely to be absorbed and, even if
absorbed, are rapidly excreted. High-molec-
ular-weight nonhalogenatic carboxylic acids
are also a low concern because they have no
structural alerts, and many are natural prod-
ucts and nutrients, U.S. Food and Drug
Administration food additives, and synthetic
flavorings. Several medium-size (6–10
carbons) carboxylic acids with branching at
the carbon next to the carboxylic group
(omega-1 carbon) were considered potential
rodent carcinogens because of potential per-
oxisome-proliferating activity but were given
a marginal concern rating because of uncer-
tain human signiﬁcance. A number of non-
halogenated aldehydes, particularly those
with high molecular weight, are given low or
marginal concern because they are unlikely
to have significant dose via drinking water;
this subject will be further discussed below.
With the exception of α,β-unsaturation or
closely spaced dicarbonyl groups, nonhalo-
genated ketones are mostly of low concern
because they lack electrophilic activity and
are generally not associated with carcino-
genicity. Halogenated aliphatic amines are a
low concern because of structural analogy to
chloramine, which has negative cancer
bioassay data (47).
The remainder (58/209) of the DBPs
fall into the low-moderate concern category
and represent a wide variety of classes, both
halogenated and nonhalogenated. In gen-
eral, these DBPs are considered to have a
concern level lower than moderate because
they have a less active chlorine/bromine
group or contain structural features that are
not as favorable for carcinogenic activity.
These DBPs include certain haloacids,
haloaldehydes, haloethers, haloamides,
nonhalogenated aromatics, and reactive
ketones. Additionally, a large number
(35/209) of haloketones, halofuranones,
haloalkanes, halonitriles, and nonhalo-
genated aldehydes are considered of low-
moderate concern. The rationale for their
assignments as well as the SAR information
available on these classes are discussed in
more detail below. 
Halofuranones, MX, and
Related Compounds
Within the halofuranones class, 3-chloro-4-
(dichloromethyl)-5-hydroxy-2(5H)-furanone
(MX) is the most well-known chemical. MX
is the most potent, direct-acting mutagenic
DBP ever tested in the Ames test (48). On a
molar basis MX alone can account for up to
30–50% of the mutagenicity of chlorinated
water (49). It is also a potent multitarget car-
cinogen in the rat (50). The upper-bound
cancer risk per unit dose (oral slope factor)
for lifetime exposure to MX (based on thy-
roid follicular adenomas in the rat) was esti-
mated (51) to be 3.7 (mg/kg-day)–1. This
number is not as high as would be expected
from its bacterial mutagenic potency, indi-
cating that MX may be readily detoxiﬁed in
the body. The structure–mutagenicity rela-
tionships of MX and related compounds
have been extensively studied using Ames
Salmonella assay (49,52,53). MX is an
extremely potent, direct-acting bacterial
mutagen; its mutagenic activity can be sub-
stantially decreased by inclusion of S-9 mix.
MX can undergo reversible cyclization
between its closed-ring and open-ring forms,
depending on the pH of the aqueous
medium. In general, MX and related com-
pounds, which are capable of undergoing
cyclization reactions, are considerably more
mutagenic than their corresponding com-
pounds, which remain predominantly in the
open-ring forms. For example, MX is at least
10 times more potent than (E)-2-chloro-3-
(dichloromethyl)-4-oxobutenoic acid
(EMX), the geometric isomer of the open-
ring form of MX with limited capacity to
cyclize (49). The hydroxy group at the 5
position, which facilitates the cyclization
reaction, also has a profound effect on deter-
mining the mutagenicity. Elimination of the
5-OH group from MX (yielding 3-chloro-4-
(dichloromethyl)-2-(5H)-furanone [red-
MX]) reduces the mutagenicity by 100-fold
(49). Apparently, the closed-ring form,
which is less hydrophilic than the open-ring
form, may be required for optimal mem-
brane penetration. It appears that the ulti-
mate mutagen of MX-related compounds
inside the cells may be their open-ring form,
but they need to cyclize to closed-ring form
outside the cells to facilitate membrane pene-
tration. Substitution of chlorine by bromine
has no appreciable effects on mutagenicity, as
indicated by comparable mutagenicity among
MX, 3-chloro-4-(bromochloromethyl)-5-
hydroxy-2(5H)-furanone (BMX-1), 3-chloro-
4-(dibromomethyl)-5-hydroxy-2(5H)-
furanone (BMX-2), and 3-bromo-4-(dibro-
momethyl)-5-hydroxy-2(5H)-furanone
(BMX-3) (53), whereas replacement of the
4-dichloromethyl group of MX by
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Table 4. Structural class and concern level distribution of DBPs under evaluation.
Total no. Concern level
Structural class of the DBP of DBPs HM M LM Mar or L
Halofuranones MX-related 10 3 (30%) 1 (10%) 4 (40%) 2 (20%)
Haloalkanes/haloalkenes 14  – 5 (36%) 6 (43%) 3 (21%)
Halonitriles 15 – 6 (40%) 7 (47%) 2 (13%)
Haloketones 18 – 2 (11%) 14 (88%) 2 (11%)
Haloaldehydes 6 – 1 (17%) 5 (83%) –
Halonitroalkanes 4 – 1 (25%) 3 (75%) –
Haloacidsa 11 – – 2 (18%) 9 (82%)
Acetate of haloalcohols 2 – – 1 (50%) 1 (50%)
Haloethers 3 – – 1 (33%) 2b (67%)
Haloamines/haloamides 6 – – 2 (33%) 4 (67%)
Haloaromatics 4 – – 2 (50%) 2 (50%)
Other halo-organics 3 – – 1 (33%) 2 (67%)
Nonhalogenated ketones 16 – – 2 (12%) 14 (88%)
Nonhalogenated aldehydes 20 – 1 (5%) 4 (20%) 15 (75%)
Nonhalogenated acids 54 – – – 54 (100%)
Nonhalogenated aromatics 9 – – 2 (22%) 7 (78%)
Other nonhalo-organics 12 – – – 12 (100%)
Inorganics 2 – – 2 (100%) –
Total 209 3 (2%) 17 (8%) 58 (28%) 131 (62%)
aExcluding several dihalo- and trihaloacetic acids previously selected for testing. bCompounds expected to hydrolyze in
water instantaneously. Concern would be HM if exposure were via inhalation.4-chloromethyl generates a less potent
mucochloric acid (52,54,55).
On the basis of this SAR information, the
cancer concern levels of the 10 MX-related
DBPs in this study are summarized in Table
5, along with rationale and available genotoxi-
city data. The three chlorobromo analogs of
MX (BMX-1, BMX-2, and BMX-3) are all
given a high-moderate rating whereas
mucochloric acid is given a moderate rating.
On the basis of weaker mutagenicity and less
favorable cyclizing capacity, EMX and red-
MX are considered to be of low-moderate
concern. Despite the lack of toxicity data, 2-
chloro-3-(dichloromethyl)-buteindioic acid
(ox-MX) and (E)-2-chloro-(dichloromethyl)-
buteindioic acid (ox-EMX) are given a mar-
ginal concern because the oxidation of the
aldehyde group is expected to eliminate
cyclizing capacity and may render the
compounds too hydrophilic. 
Haloalkanes and Haloalkenes
Numerous haloalkanes and haloalkenes have
been tested for carcinogenic and mutagenic
activities; the SARs have been extensively
studied (56). In general, the genotoxic poten-
tial is dependent on the nature, number, and
position of halogen(s) and the molecular size
of the compound. Short-chain monohalo-
genated (excluding fluorine) alkanes and
alkenes are potential direct-acting alkylating
agents, particularly if the halogen is at the ter-
minal end of the carbon chain or at an allylic
position. Dihalogenated alkanes are also
potential alkylating or cross-linking agents
(either directly or after GSH conjugation),
particularly if they are vicinally substituted
(e.g., 1,2-dihaloalkane) or substituted at the
two terminal ends of a short to medium-size
(e.g., 2–7) alkyl moiety (i.e., α,ω´-
dihaloalkane). Fully halogenated haloalkanes
tend to act by free radical or nongenotoxic
mechanisms (such as generating peroxisome-
proliferative intermediates) or undergo reduc-
tive dehalogenation to yield haloalkenes that
in turn could be activated to epoxides.
Haloalkenes are of concern because of poten-
tial to generate genotoxic intermediates after
epoxidation. The concern for haloalkenes
may be diminished if the double bond is
internal or sterically hindered.
On the basis of the above SAR informa-
tion, the cancer concern levels of the 14
haloalkanes and haloalkenes in this study are
summarized in Table 6 along with rationale
and available screening cancer bioassay
Reviews, 2002 • Woo et al.
82 VOLUME 110 | SUPPLEMENT 1 | February 2002 • Environmental Health Perspectives
Table 5. Halofuranones and MX-related compounds.
Concern
DBP Structure level Rationale
1. 3-Chloro-4-(bromochloromethyl)- HM Structural analogy to MX, which has been shown to be a multitarget 
5-hydroxy-2(5H)-furanone (BMX-1) carcinogen in the rat (50). 
Positive mutagenicity data in the Ames test for all three compounds with
potency comparable to that of MX (53).
2. 3-Chloro-4-(dibromomethyl)- HM The rationale above applies to BMX-2.
5-hydroxy-2(5H)-furanone (BMX-2)
3. 3-Bromo-4-(dibromomethyl)- HM The rationale above applies to BMX-3.
5-hydroxy-2(5H)-furanone (BMX-3)
4. 2,3-Dichloro-4-oxobutenoic acid M Structural analogy to MX with Cl 5-hydroxy-2(5H)furanone) expected to 
(mucochloric acid; 3,4-dichloro-5- be less reactive. Positive genotoxicity data (Ames, E. coli, sister chromatid 
hydroxy-2(5H)-furanone) exchange in Chinese hamster ovary cells) but less active than MX (54,55,74). 
5. (E)-2-Chloro-3-(dichloromethyl)- LM The diastereoisomer of the open-ring form of MX with limited capacity to
4-oxobutenoic acid (EMX) cyclize. Positive Ames assay but much less potent than MX (49).
6. 3-Chloro-4-(dichloromethyl)-2- LM Structural analogy to MX but lacking the important 5-OH group.
(5H)-furanone (red-MX) Positive Ames assay but much less potent than MX (52,74).
7. Dihydro-4,5-dichloro-2(3H)-furanone LM Active chlorine, possible acylating agent, possible GSH-mediated activation
of vicinally substituted chlorine, may generate haloaldehyde after 
ring opening.
8. 5-Hydroxy-5-trichloromethyl-2-furanone LM α,β-Unsaturated lactone that may undergo conjugate Michael addition
with nucleophiles. Structural analogy to carcinogenic β-angelicalactone (65). 
9. 2-Chloro-3-(dichloro methyl)- Mar Structural analogy to the open-ring form of MX, but oxidation of the
butenedioic acid (ox-MX) aldehyde group eliminates cyclizing capability and may render the compound
too hydrophilic.
10. (E)-2-Chloro-3-(dichloro methyl)- Mar Structural analogy to the open-ring form of EMX, but oxidation of the 
butenedioic acid (ox-EMX) aldehyde group eliminates cyclizing capability and may render the compound
too hydrophilic.
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Y Z(pulmonary adenoma assay) and genotoxicity
data. Five brominated and iodinated
methane and ethane derivatives are given a
moderate rating. Beyond the fact that
bromine and iodine are better leaving groups
than chlorine, there is also evidence that
brominated THMs may be preferentially
activated by a theta-class glutathione S-trans-
ferase (GSTT1-1) to mutagens in Salmonella
even at low substrate concentrations (57,58).
Furthermore, there are human carcinogenic-
ity implications because of polymorphism in
GSTT1-1. Human subpopulations with
expressed GSTT1-1 may be at a greater risk
to brominate THMs than humans who lack
the gene (57). Six, two, and one haloalkanes/
haloalkene(s) are given low-moderate, mar-
ginal, and low concern, respectively, with
detailed rationale summarized in Table 6.
Halonitriles
There are basically three types of halonitriles
detected as DBPs: a) halogenated acryloni-
trile and higher congeners, b) halogenated
acetonitriles and higher congeners, and
c) cyanogen halides. The predicted concern
levels of these compounds are summarized in
Table 7 along with rationale and available
screening data.
Three DBPs in this class are chlorinated
acrylonitriles (cis- and trans-2,3,4-trichloro-
2-butenenitrile and trichloropropenenitrile);
they have all been given a moderate concern
rating. Acrylonitrile is a well-known geno-
toxic rodent carcinogen (59). The introduc-
tion of halogens to acrylonitrile may reduce
the potential to undergo Michael addition or
epoxidation, but the terminal chlorine in cis-
and trans-2,3,4-trichloro-2-butenenitrile
may introduce an additional reactive termi-
nal chlorine. Trichloropropenenitrile is of
concern because of its structural analogy
to tetrachloroethene.
Acetonitrile is not carcinogenic in
rodents and is only weakly or marginally
mutagenic (60). The introduction of halogen
to α- and terminal carbons is expected to
increase genotoxic potential by making it an
alkylating/cross-linking agent. Halogenated
acetonitriles have been tested in various
cancer and genotoxicity screening assays.
Table 8 summarizes and compares the avail-
able data. On the basis of alkylating activity,
the brominated compounds are expected to
be more reactive than chlorinated com-
pounds. On the basis of data for chlorinated
acetonitriles, and consistent with chemistry
of halogenated compounds, increasing halo-
genation tends to decrease alkylating activity.
Essentially mixed results have been observed
in the screening assays. Despite their higher
alkylating activity, monohalogenated acetoni-
triles tend to be inactive in a number of in
vitro genotoxicity assays, probably because of
complication by their higher cytotoxicity.
There is some evidence that, in Comet,
Chinese hamster ovary, and newt micronu-
cleus assays, increasing chlorination increases
the genotoxic potency (Table 8). However,
this pattern is not seen in lung adenoma assay
and skin tumor initiation studies in SEN-
CAR mice. Probably the only consistent pat-
tern seen across various assays is the higher
activity of dibromoacetonitrile and bro-
mochloroacetonitrile. Dibromoacetonitrile
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Table 6. Haloalkanes and haloalkenes.
DBP Structure Concern level Rationale
1. Dibromomethane CH2Br2 M Structural analogy to dichloromethane, which is a rat carcinogen (47). The brominated compound is 
expected to be more hazardous than the chlorinated compound because of more favorable 
leaving tendency and GSH-mediated activation. Positive genotoxicity (Ames, ara forward mutation, 
E. coli) data (75–78).
2. Bromochloromethane CH2BrCl M Structural analogy to dichloromethane, which is a rat carcinogen (47). The brominated compound is 
expected to be more hazardous than the chlorinated compound because of more favorable 
leaving tendency and GSH-mediated activation.
3. Bromochloroiodomethane CHBrClI M Structural analogy to bromodichloromethane, which is a rodent carcinogen (47). The iodo group is 
expected to be a better leaving group than chloro group. 
4. Dichloroiodomethane CHCl2IM Structural analogy to bromodichloromethane and chloroform, which are both carcinogenic (47). The 
iodo group is expected to be an even better leaving group than the chloro/bromo group.
5. 1,1,1-Tribromo-2-bromo-2- Br3C–CHBrCl M Structural analogy to pentachloro-ethane, which is a mouse carcinogen (47), and 1,1,2,2-tetra-
chloroethane bromoethane, which is hepatotoxic.
6. Chloromethane CH3Cl LM Structural analogy to iodomethane (56) and chloroethane (47), which are both carcinogenic. Positive 
Ames assay (56).
7. 2-Bromobutane CH3CH2CH(Br)CH3 LM  Positive lung adenoma assay and positive Ames assay (56). The internal location of bromine may 
(sec-butyl bromide) limit its genotoxic potential. 
8. 2,3-Dichlorobutane CH3CH(Cl)CH(Cl)CH3 LM Vicinal dichloro substitution may lead to GSH-mediated activation, but internal location of chlorine 
may limit its genotoxic potential. 
9. 3,3,3-Trichloro-2-methyl- Cl3CC(CH3)=CH2 LM Structural analogy to 1,3-dichloropropene, which is a mouse carcinogen (47) but not as favorable
1-propene because of steric hindrance by methyl and marginally active trichloro group.
10. 1,2-Dichloro-2-methyl- ClCH2C(Cl)(CH3)CH2CH3 LM Structural analogy to 2-chloroisobutane, which is positive in the lung adenoma assay (56). Vicinal 
butane substitution may lead to GSH-mediated activation, but methyl substitution may lead to steric 
hindrance.
11. Tetrachlorocyclopropene  LM Limited structural analogy to hexachloropentadiene, which has negative bioassay data (47). However, 
this compound may have some genotoxic potential. One of the chlorines at the bridged carbon may 
leave and generate a carbonium ion that can be stabilized by the ring by resonance stabilization.
12. 1,1,5,5-Tetrachloropentane Cl2CH(CH2)3CHCl2 Mar Potential alkylating agent, but its genotoxic potential may be reduced because the potentially reactive 
terminal carbons are both dichlorinated, making them not as favorable as mono chlorine as leaving 
groups.
13. 1-Chlorooctane ClCH2(CH2)6CH3 Mar Despite the presence of a terminal chlorine, this compound is expected to be a weak alkylating agent 
because of its high molecular weight and its saturated chain.
14. 2-Chlorododecane CH3CH(Cl)(CH2)9CH3 L Expected to be a very weak alkylating agent because of its high molecular weight and its 
saturated chain.
Cl Cl
Cl Clhas already been selected for testing (Table
2). In this study, bromochloroacetonitrile has
been given a moderate concern, whereas all
other halogenated acetonitriles have been
given a low-moderate concern. Two higher
homologs of bromochloroacetonitriles (2,3-
dichloro-3-bromopropanenitrile and 3,4-
dichlorobutanenitrile) have also been
considered of moderate concern because of
SAR consideration, although they should be
at the low end of the moderate category.
Cyanogen chloride and cyanogen bro-
mide have been given a low concern. They
are known or expected to be metabolized to
cyanide in the body. The expected high
acute toxicity should limit signiﬁcant expo-
sure. There are also no structural alerts
suggestive of carcinogenic potential.
Haloketones
Haloketones with monosubstitution with
chlorine or bromine at the α-carbon or ter-
minal carbon are expected to be potential
alkylating agents. Haloketones with active
halogen at both ends of the aliphatic chain
are expected to be cross-linking agents. The
leaving tendency of halogen tends to decrease
with an increase in the degree of halogena-
tion as the electron-withdrawing effect of the
second and/or third halogen diminishes the
leaving potential of the first halogen
(22,48,56). On the other hand, haloketones
with multiple halogenation at both α-car-
bons may lead to unstable compounds. The
stability of several chlorinated ketones in
aqueous solutions follows this order: 1,3-
dichloro > pentachloro >> hexachloro (61).
A variety of haloketones have been tested
in various screening assays. Consistent with
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Table 7. Halonitriles and cyanogen halides.
DBP Structure Concern level Rationale
1. cis-2,3,4-Trichloro-2-butene nitrile M This compound is a substituted acrylonitrile, a probable human carcinogen (79). Although the 
substitutions may reduce potential to undergo Michael addition or epoxidation, the terminal 
active chlorine may provide additional genotoxic potential.
2. trans-2,3,4-Trichloro-2-butene nitrile M This compound is a substituted acrylinitrile, a known rodent carcinogen (79). Although the 
substitutions may reduce potential to undergo Michael addition or epoxidation, the terminal 
active chlorine may provide additional genotoxic potential. 
3. Bromochloroacetonitrile BrClCHCN M This compound has active halogens. Positive skin tumor initiator (80), positive in lung 
adenoma assay (81), and positive genotoxicity (SOS, Ames, sister chromatid exchange, 
newt micronucleus) data (47,69,80,82–84). 
4. 2,3-Dichloro-3-bromopropanenitrile BrClCHCH(Cl)CN M This compound has vicinally substituted active halogens and may have genotoxic potential 
via GSH-mediated activation. Concern level at the low end of M.
5. 3,4-Dichlorobutanenitrile ClCH2CH(Cl)CH2CN M This compound has vicinal dichloro substitution and may have genotoxic potential via GSH-
mediated activation. Concern level at the low end of M.
6. Trichloropropenenitrile M This compound is a substituted acrylonitrile, a probable human carcinogen (79), but the 
chlorines may reduce the potential to undergo Michael addition or epoxidation. Because
cyano group may be considered a pseudo halogen, the compound is also a structural analogy 
of perchloroethylene, a rodent carcinogen (47).
7. Bromoacetonitrile BrCH2CN LM This compound has an active bromine but negative or mixed genotoxicity data (69,83,84), due 
possibly to its cytotoxicity.
8. Chloroacetonitrile ClCH2CN LM This compound has an active chlorine. Positive skin tumor initiator (80) and positive in lung 
adenoma assay (81) but negative or mixed genotoxicity data (69,83,84) due possibly to its 
cytotoxicity.
9. Dichloroacetonitrile Cl2CHCN LM This compound has a somewhat active chlorine. Negative in skin tumor initiation and lung 
adenoma assays (80,81); some positive and some equivocal genotoxicity data (69,83,84).
10. Tribromoacetonitrile Br3CCN LM This compound is structurally related to trichloroacetonitrile, with bromine expected to be 
a better leaving group than chlorine.
11. Bromodichloroacetonitrile BrCl2CCN LM This compound is structurally related to trichloroacetonitrile, with bromine expected to be 
a better leaving group than chlorine.
12. Dibromochloroacetonitrile Br2ClCCN LM This compound is structurally related to trichloroacetonitrile, with bromine expected to be 
a better leaving group than chlorine.
13. Trichloroacetonitrile Cl3CCN LM This compound is positive in skin tumor initiation and lung adenoma assays (80,81) but has 
mixed genotoxicity data (69,83,84).
14. Cyanogen chloride ClCN L This compound is known to be readily metabolized to cyanide in the body. The expected high 
acute toxicity should limit signiﬁcant exposure. There is also no structural alert suggestive of 
cancer concern.
15. Cyanogen bromide BrCN L This compound is expected to behave in the same way as cyanogen chloride.
Cl
Cl
Cl
CN
Cl Cl
Cl CN
Cl
Cl
Cl
CN
Table 8. Comparison of chemical, biochemical, and biologic properties of haloacetonitriles.
Chemical/biochemical/biologic 
properties relevant to assessing  Relative order of potency of 
carcinogenic potential haloacetonitriles tested Reference
Alkylating activity 4-(p-nitrobenzyl)pyridine Br2 >> BrCl > Cl >> Cl2 >> Cl3  (82)
reaction)
Inhibition of glutathione S-transferase Cl3 > Br2 > Cl2 > Br > Cl (85)
E. coli SOS chromotest BrCl > Br2 > Cl2 >> Cl (inactive) (83)
Ames or Ames ﬂuctuation tests Cl2 ≈ BrCl > Cl3 ≈ Br2 > Cl ≈ Br (inactive) (69,84)
Cl3 > Cl > Cl2 > Br2 ≈ Br (inactive)
DNA single-strand breaks in  Cl3 > BrCl > Br2 > Cl2 > Cl  (69,84)
HeLa cell (comet assay) Br2 > Cl3 ≈ Cl2 ≈ BrCl > Cl
Sister chromatid exchanges in Chinese  Br2 > BrCl > Cl3 ≥ Cl2 > Cl (80)
hamster ovary cells
Newt micronucleus assay Br2 ≥ Cl3 > Br > Cl2 >> Cl (83)
In vivo mouse micronucleus assay Br2 ≈ BrCl ≈ Cl3 ≈ Cl2 ≈ Cl (all inactive) (80)
Lung adenoma assay in strain A mice Cl ≈ Cl3 ≈ BrCl > Br2 ≈ Cl2 (inactive) (81)
Skin tumor initiation in SENCAR mice Br2 ≈ Cl ≈ BrCl > Cl3 (inconsistent) > Cl2 (inactive) (80)their potential chemical reactivity as alkylating
agents, three chloropropanones have been
shown to react directly with GSH. Their rel-
ative potency follows this order: 1,3-dichloro
> monochloro > 1,1-dichloro (62). Among
five chloropropanones (mono-, 1,1-, 1,3-,
1,1,1-, and 1,1,3-) tested for skin tumor–ini-
tiating activity in SENCAR mice, only 1,3-
dichloropropanone showed clearly positive
results (63). With the exception of 1,1,1,3-
tetrachloropropanone, all congeners of
chloropropanones have been tested for
mutagenicity in the Ames test. Among the
mutagenic chloropropanones (mostly direct-
acting), the relative mutagenic potency fol-
lows this order: 1,3- > 1,1,3,3- > penta- >
1,1,3- > 1,1,1- > 1,1-, with the potency of
1,3- being about 100 to 1,000 times higher
than that of 1,1- (48,62). Inconsistent
results have been observed in the Ames test
on monochloropropanone because of its
high cytotoxicity (which to some extent can
be attenuated by inclusion of S9 mix) and
on hexachloropropanone, which is relatively
unstable in water (61). 1,3-Dichloro and, to
a lesser extent, 1,1,3-trichloro congeners
have also been consistently found to be more
mutagenic than mono-, 1,1-, and 1,1,1-
congeners in E. coli SOS chromotest for
DNA damage (SOS), Ames ﬂuctuation, and
newt micronucleus tests (64). 
Based on the above SAR and screening
data, the cancer concern levels of 19
haloketones are summarized in Table 9
along with rationale and available data.
Only 1,3-dichloropropanone and, to a
lesser extent, 1,1,3-trichloropropanone
have been given a moderate concern. Most
of the other haloketones have been given a
low-moderate concern, although there may
be slight differences within the low-moder-
ate category as detailed in the rationale of
individual compounds.
Nonhalogenated Aldehydes
As a class, aldehydes have been given special
attention tailored to drinking water consid-
eration. Essentially, aldehydes are elec-
trophilic, reactive chemicals that may form
DNA–protein cross-links and induce car-
cinogenesis/mutagenesis. A variety of aldehy-
des have been tested for carcinogenic activity
(65). By the inhalation route formaldehyde
and, to a much lesser extent, acetaldehyde
are carcinogenic, whereas isobutyraldehyde is
not carcinogenic even at doses that cause
irritation to the respiratory tract. There is
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Table 9. Haloketones.
Concern
Compound Structure level Rationale
1. 1,3-Dichloropropanone ClCH2C(O)CH2Cl M This compound is a potential cross-linking agent via its active chlorine at both termini. Positive skin tumor 
initiator (63) and positive genotoxicity data (Ames, SOS, newt micronucleus) and strong GSH depletor 
(48,86,87).
2. 1,1,3-Trichloropropanone Cl2CHC(O)CH2Cl M This compound is a potential cross-linking agent. Negative skin tumor initiator (63) but consistently positive
genotoxicity data (48,86). Concern level at the low end of M.
3. 1,1,3,3-Tetrachloropropanone Cl2CHC(O)CHCl2 LM This compound has the potential to be a cross-linker via its chlorines at both termini, but the disubstituted 
chlorines are not as reactive as monosubstituted chlorine. Positive Ames (48).
4. 1,1,1,3-Tetrachloropropanone Cl3CC(O)CH2Cl LM This compound has the potential to be a cross-linker via its chlorines at both termini, but the trisubstituted 
chlorines are only marginally active.
5. Chloropropanone ClCH2C(O)CH3 LM This compound has an active chlorine and is a good GSH depletor (87). Negative skin tumor initiator (63); 
mixed genotoxicity (–SOS, +/–Ames, –newt micronucleus) data (48,86,87).
6. 1,1-Bromochloropropanone BrClCHC(O)CH3 LM Structural analogy to 1,1-dichloropropanone but with bromine expected to be a better leaving group than 
chlorine.
7. 1,1-Dibromopropanone Br2CHC(O)CH3 LM Structural analogy to 1,1-dichloropropanone but with bromine expected to be a better leaving group than 
chlorine.
8. Pentachloropropanone Cl3CC(O)CHCl2 LM Marginally active chlorines. Positive Ames test (48), but the extensive chlorine substitution makes the 
compound unstable at high pH (80).
9. 1,1,1-Trichloropropanone Cl3CC(O)CH3 LM The chlorines at the trisubstituted terminus are only marginally active. Negative skin tumor initiator (63).
Weak or mixed genotoxicity (w+SOS, w+Ames, –newt micronucleus) data (48,86). Concern level at low 
end of LM.
10. 1-Bromo-1,1-dichloropropanone BrCl2CC(O)CH3 LM Structural analogy to 1,1,1-trichloropropanone. The halogens are only marginally active. Concern level at 
low end of LM.
11. Hexachloropropanone Cl3CC(O)CCl3 LM Marginally active chlorines. Ames test is negative or inconsistent and solvent dependent (48,89). The 
extensive chlorine substitution makes the compound unstable even at near neutral pH (89). Concern level at 
low end of LM.
12. 1,1-Dichloro-2-butanone CH3CH2C(O)CHCl2 LM Structural analogy to 1,1-dichloropropanone. The chlorines are only somewhat active. Concern level at low 
end of LM.
13. 1,1-Dichloropropanone Cl2CHC(O)CH3 LM The chlorines are somewhat active. Negative skin tumor initiator (63). Weak or mixed genotoxicity (+SOS, 
w+Ames, –newt micronucleus) data (48,86,87). Concern level at low end of LM.
14. 1,1,1-Trichloro-2-butanone CH3CH2C(O)CCl3 LM Structural analogy to 1,1,1-trichloropropanone. The chlorines at the trisubstituted terminus are expected to
be marginally active. Concern level at low end of LM.
15. 2,2,4-Trichloro-1,3-cyclo- LM This compound is an α,β-unsaturated ketone with at least one β-position available for Michael addition. 
The pentenedione chlorines at 2-position may be somewhat active. Concern level at low end of LM.
16. 2-Chlorocyclohexanone LM The unsubstituted cyclohexanone is a weak to marginally active carcinogen (90). The introduction of active 
chlorine at the a-carbon expected to increase genotoxic potential, but the rigid ring may limit its potential. 
Concern level at low end of LM.
17. 3,3-Dichloro-2-butanone CH3C(Cl2)C(O)CH3 Mar The chlorines are only marginally active and are not terminal.
18. 2,2-Dichloro-3-pentanone CH3CH2C(O)C(Cl2)CH3 Mar The chlorines are only marginally active and are not terminal.
O
O Cl
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Clsome suggestive evidence that acetaldehyde
may be a potential ultimate carcinogen in
alcoholics with genetically deﬁcient detoxify-
ing capabilities; however, the subject remains
to be resolved. By the oral route, the α,β-
unsaturated aldehyde, crotonaldehyde, is
carcinogenic, whereas acrolein is equivocal,
probably because it is too reactive. 
Numerous aldehydes have been tested
for mutagenic activity. In general, only
short-chain aldehydes (e.g., formaldehyde,
acetaldehyde) have been clearly shown to
be mutagenic. The genotoxic potential of
aldehydes decreases substantially with an
increase in molecular size. The introduc-
tion of hydrophilic groups generally
decreases activity, whereas α,β-unsatura-
tion tends to increase the genotoxic poten-
tial provided that the β-position is not
sterically hindered (66).
Although short-chain aldehydes such as
formaldehyde and acetaldehyde are carcino-
genic in animals by inhalation, their car-
cinogenic potential by the oral route may be
limited unless exposure occurs in high doses
that overwhelm the detoxification mecha-
nisms or to susceptible individuals. There is
some evidence that hexamethylenete-
tramine, which is known to be hydrolyzed
to formaldehyde and shown to induce local
sarcomas by injection, has no carcinogenic
activity when tested by the oral route (65).
With the exception of α,β-unsaturated alde-
hydes, our assessment of the cancer hazard
potential of aldehydes is based on the
assumption that the principal route of expo-
sure is oral and that the general population
has adequate capacity to detoxify environ-
mental levels of aldehydes. Humans are
known to have genetic polymorphism in
aldehyde dehydrogenase-2 (ALDH-2), and
there is some suggestive (67) but inconsis-
tent (68) evidence that subpopulations with
deficient ALDH-2 may be at a higher
cancer risk to acetaldehyde generated from
consuming alcohol. 
Among the nonhalogenated aldehydes
considered in this study, butanedial is the
only compound that has been given a moder-
ate concern. Despite the lack of toxicity data,
butanedial has been given a higher concern
than the rest of the compounds because it has
two terminal reactive aldehydes separated by
two methylene groups, which should make it
a highly favorable cross-linking agent. Four
aldehydes (methyl glyoxal, cyanoformalde-
hyde, 2-hexenal, and propanal) are consid-
ered to be of low-moderate concern if they
could be found in water in significant
amounts. Higher molecular-weight aldehy-
des are not of significant concern by SAR
consideration and comparison to isobu-
tyraldehyde, which is not carcinogenic even
by the inhalation route. 
Summary and Conclusions
Determining appropriate drinking water
DBP regulations is a complex problem.
Disinfectants are necessary to protect against
waterborne pathogens, and thus DBPs are
unavoidable. Source water quality and con-
stituents vary widely throughout the United
States. Combined with the assortment of
disinfectants available, this means that DBPs
differ from site to site in both occurrence
and concentration. Along with a number of
DBPs that have some occurrence data, there
are hundreds of chemicals that have been
identiﬁed as DBPs but that have no quanti-
tative occurrence data beyond this single
identiﬁcation. The conundrum presented by
these hundreds of identiﬁed DBPs is how to
determine research priorities. Two impor-
tant factors to consider in setting regulations
are the toxicity of the chemical and the con-
centration at which the chemical is found.
For the majority of the chemicals in this arti-
cle, no data were available on either factor.
Gathering occurrence data and toxicity test-
ing are both expensive and time-consuming
activities. SAR analysis is essential in narrow-
ing down health research priorities because it
is time and cost effective. The U.S. EPA
efforts are ongoing to gather occurrence data
for a number of DBPs of higher concern. 
It is encouraging from a public health
standpoint that although more than 200
DBPs were analyzed, only 20 were of moder-
ate or higher concern for carcinogenic poten-
tial. Of these, four are structurally related to
MX, which is believed to occur at very low
levels (nanograms per liter), and are thus
likely not of great concern. Five others are
halogenated alkanes, which presumably will
be controlled by existing and future THM
regulations. As a result of this analysis, the
most suitable candidates for testing are the
halonitriles and haloketones that are in the
moderate concern category, dibromoni-
tromethane and butanedial.
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